不同抗骨质疏松药物一年和两年持续用药情况:一项回顾性队列研究
该回顾性队列研究利用真实世界数据库纳入19253名≥50岁女性抗骨质疏松药物新使用者,评估1年和2年持续用药率。2年未调整持续率从10.3%(雷奈酸锶)到45.4%(地舒单抗);与阿仑膦酸钠相比,地舒单抗2年停药风险调整后HR为0.60(95%CI 0.56-0.64)。作者认为未测量的适应证混杂可能部分解释该发现。
要点
- 2年未调整持续率范围为10.3%至45.4%,雷奈酸锶最低、地舒单抗最高。
- 1年末特立帕肽和地舒单抗停药风险低于阿仑膦酸钠,调整后HR分别为0.76和0.54。
- 2年末仅地舒单抗停药风险低于阿仑膦酸钠,调整后HR为0.60(95%CI 0.56-0.64)。
核心结论
- 未调整的2年持续用药率不理想。
- 与阿仑膦酸钠使用者相比,特立帕肽和地舒单抗使用者1年持续用药更好,仅地舒单抗使用者2年持续用药更好。
- 未测量的适应证混杂可能部分解释本研究发现。
研究设计与样本
- 回顾性队列研究,使用匿名记录和配药数据(www.sidiap.org)。
- 纳入标准为年龄≥50岁女性、2012年抗骨质疏松药物新使用者、治疗开始前至少有12个月可用数据。
- 排除其他骨病/治疗和少见抗骨质疏松药物(N<100)。
- 随访从首次药房配药至停药、研究结束、删失或换药。
- 共纳入19253名女性。
主要发现
- 未调整2年持续率[95%CI]从10.3%[9.1-11.6%](雷奈酸锶)到45.4%[43.1-47.8%](地舒单抗)。
- 1年持续率从35.8%[33.9%-37.7%](雷奈酸锶)到65.8%[63.6%-68.0%](地舒单抗)。
- 第一年末与阿仑膦酸钠使用者相比,特立帕肽和地舒单抗使用者停药风险降低,调整后HR分别为0.76(95%CI 0.67-0.86)和0.54(95%CI 0.50-0.59)。
- 第二年末与阿仑膦酸钠使用者相比,仅地舒单抗使用者停药风险更低,调整后HR为0.60(95%CI 0.56-0.64)。
关键数值与推荐
- 持续用药定义为允许最多90天的用药间隙。
- Cox模型估计停药风险比,调整年龄、性别、BMI、吸烟、饮酒、Charlson合并症指数、既往骨折、抗骨质疏松药物使用、口服糖皮质激素和社会经济状况。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未测量的适应证混杂可能部分解释本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Adherence to anti-osteoporosis medications is poor. We carried out a cohort study using a real-world population database to estimate the persistence of anti-osteoporosis drugs. Unadjusted 2-year persistence ranged from 10.3 to 45.4%. Denosumab users had a 40% lower risk of discontinuation at 2 years compared to alendronate users. PURPOSE: The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications. METHODS: This is a retrospective cohort using data from anonymised records and dispensation data ( www.sidiap.org ). Eligibility comprised the following: women aged ≥50, incident users of anti-osteoporosis medication (2012), with data available for at least 12 months prior to therapy initiation. Exclusions are other bone diseases/treatments and uncommon anti-osteoporosis drugs (N < 100). Follow-up was from first pharmacy dispensation until cessation, end of study, censoring or switching. Outcomes are 2- and 1-year persistence with a permissible gap of up to 90 days. Persistence with alendronate was compared to other bisphosphonates, strontium ranelate, selective oestrogen receptor modulators, teriparatide and denosumab. Cox models were used to estimate hazard ratios of therapy cessation according to drug used after adjustment for age, sex, BMI, smoking, alcohol drinking, Charlson co-morbidity index, previous fractures, use of anti-osteoporosis medication/s, oral corticosteroids and socio-economic status. RESULTS: A total of 19,253 women were included. Unadjusted 2-year persistence [95% CI] ranged from 10.3% [9.1-11.6%] (strontium ranelate) to 45.4% [43.1-47.8%] (denosumab). One-year persistence went from 35.8% [33.9%-37.7%] (strontium ranelate) to 65.8% [63.6%-68.0%] (denosumab). At the end of the first year and compared to alendronate users, both teriparatide and denosumab users had reduced cessation risk (adjusted HR 0.76, 95% CI 0.67-0.86 and 0.54, 95% CI 0.50-0.59 respectively) while at the end of the second year, only denosumab had a lower risk of discontinuation (adjusted HR 0.60, 95% CI 0.56-0.64). CONCLUSIONS: Unadjusted 2-year persistence is suboptimal. However, both teriparatide and denosumab users had better 1-year persistence and only denosumab had 2-year better persistence compared to alendronate users. Unmeasured confounding by indication might partially explain our findings.
引用
- Reyes C, Tebe C, Martinez-Laguna D, et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017. PMID: 28714038. doi:10.1007/s00198-017-4144-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。